We've been paying close attention for years. But the market doesn't pay close attention to little upstart biotechs, nor should we expect it to.
We've just scored our first revenue. We're just being born. Until we see multiple revenue streams, and clear our various clouds, we're going to remain a low volume stock whose price is highly vulnerable to manipulation and random volatility.
It doesn't matter how much time goes by. We don't "get credit" for that. Companies (and their stocks) don't mature from passage of time, they mature by securing revenue and reputation. So however long that takes is how long it'll be until proper attention is paid and our stock price is where it ought to be.
Until then, you can watch the chart if you'd like, but it's not going to indicate anything particularly meaningful. Just a few chuckleheads trading shares around.